Which medications in the drug class Soluble Guanylate Cyclase (sGC) Stimulators are used in the treatment of Idiopathic Pulmonary Arterial Hypertension?

Updated: Jul 08, 2020
  • Author: Ronald J Oudiz, MD, FACP, FACC, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Soluble Guanylate Cyclase (sGC) Stimulators

Soluble guanylate cyclase (sGC) is an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). Pulmonary arterial hypertension (PAH) is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO-sGC-cGMP pathway.

Riociguat is the first sGC stimulator approved in the United States. Approval was based on data from the 2 randomized, double-blind, placebo-controlled, global phase III studies CHEST-1 and PATENT-1, as well as long-term data from these studies. In each study, riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.

Riociguat (Adempas)

Riociguat elicits a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding, and it directly stimulates sGC via a different binding site, independently of NO. It is indicated for chronic thromboembolic pulmonary hypertension and PAH.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!